Keyphrases
Antiphospholipid Syndrome
100%
Antiphospholipid Antibodies
39%
Obstetric Outcomes
21%
Hydroxychloroquine
19%
Autoimmune Disease
17%
During Pregnancy
16%
Sydney
16%
European Registries
15%
COVID-19
15%
Thrombosis
13%
Obstetric Complications
13%
Autoimmune
12%
Inflammatory Syndrome
12%
Hyperinflammation
9%
Low Molecular Weight Heparin
9%
Obstetric APS
9%
Statins
8%
Obstetric Morbidity
8%
Between-group
8%
Pregnant Women
8%
Non-criteria
8%
Thrombotic
8%
Antiphospholipid Antibody Profile
7%
Systemic Lupus Erythematosus
7%
Preeclampsia
7%
Low-dose Aspirin
7%
Maternal Outcomes
7%
Coronavirus 2
6%
Severe Coronavirus Disease 2019
6%
Phosphatidylinositol
6%
Anti-phosphatidylserine
6%
Systemic Autoimmune Diseases
6%
Inherited Thrombophilia
6%
Thrombophilic Disorders
6%
Atorvastatin
6%
Low Complement
6%
Systemic Lupus
6%
Obstetric History
6%
Lactation
6%
Multicenter Retrospective Study
6%
Clinical Value
6%
Bleeding
6%
Fetomaternal Outcome
6%
Immune Disease
6%
Complement Levels
6%
Therapeutic Value
6%
Disease Association
6%
Immunosuppressive Drugs
6%
Cyclophosphamide
6%
Antithrombotic Therapy
6%
Medicine and Dentistry
Antiphospholipid Syndrome
84%
Obstetrics
57%
Antiphospholipid Antibody
23%
Diseases
16%
Hydroxychloroquine
14%
Autoimmune Disease
12%
Retrospective Study
12%
Obstetric Complication
12%
Thrombosis
8%
Acetylsalicylic Acid
8%
Low Drug Dose
7%
Systemic Lupus Erythematosus
7%
Lupus Erythematosus
6%
Tumor Necrosis Factor
6%
Prevalence
6%
Antithrombotic Therapy
6%
Thrombophilia
6%
Secondary Prevention
6%
Biological Product
6%
COVID-19
6%
Systematic Review
6%
Acute Intermittent Porphyria
6%
Serositis
6%
Proteomics
6%
Immunosuppressive Drug
6%
Lactation
6%
Biocompatible Material
6%
Cyclophosphamide
6%
Rheumatic Disease
6%
Biological Phenomena and Functions Concerning the Entire Organism
6%
Adjuvant
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antiphospholipid Syndrome
37%
Antiphospholipid Antibody
23%
Disease
20%
Autoimmune Disease
18%
Hydroxychloroquine
16%
Thrombosis
11%
Inflammation
8%
Preeclampsia
7%
Immunosuppressive Agent
7%
Prevalence
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
6%
Tumor Necrosis Factor
6%
Pravastatin
6%
Systemic Lupus Erythematosus
6%
Acute Intermittent Porphyria
6%
Alpha Adrenergic Receptor Blocking Agent
6%
Rheumatic Disease
6%
Coronavirinae
6%
Thrombophilia
6%
Adjuvant
6%
Antiviral Therapy
6%
Biomaterial
6%
Azathioprine
6%
Phosphatidylinositol
6%
Corticotropin
6%
Phosphatidylserine
6%
